Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication

An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.

Doctor with Mammography - Image — AstraZeneca and Daiichi Sankyo announced positive topline results for Enhertu in second-line breast cancer • Source: Shutterstock

AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (trastuzumab deruxtecan) inched closer to a second-line HER2-positive breast cancer indication with the announcement of positive topline results of a Phase III study, thereby expanding an opportunity that was the subject of a nearly $7bn pact between the two companies in 2019.

A second-line approval would move Enhertu into a similar setting as Seagen Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.